bpc 157 safety concerns This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA will make bpc 157 safety and effectiveness

(5.3) Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported

Studies have shown that CJC-1295, Ipamorelin, and Tesamorelin significantly increase GH and IGF-1 levels in both men and women

Response: We thank the commenters for their support

At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable

It does not constitute medical advice, diagnosis, or treatment recommendations

Both CDC and FDA emphasize careful sterile handling during preparation